CL2020000096A1 - Uso de wx-uk1 y su profármaco, wx-671, para el tratamiento de enfermedades no cancerosas. - Google Patents
Uso de wx-uk1 y su profármaco, wx-671, para el tratamiento de enfermedades no cancerosas.Info
- Publication number
- CL2020000096A1 CL2020000096A1 CL2020000096A CL2020000096A CL2020000096A1 CL 2020000096 A1 CL2020000096 A1 CL 2020000096A1 CL 2020000096 A CL2020000096 A CL 2020000096A CL 2020000096 A CL2020000096 A CL 2020000096A CL 2020000096 A1 CL2020000096 A1 CL 2020000096A1
- Authority
- CL
- Chile
- Prior art keywords
- animal
- treatment
- pharmaceutically acceptable
- pharmaceutical composition
- cancerous condition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/976—Trypsin; Chymotrypsin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invención se relaciona con métodos para tratar un animal que tiene una afección no cancerosa que se mejora por el tratamiento con un inhibidor de tripsina, el método comprende obtener una muestra biológica del animal; probar la muestra para obtener una concentración de tripsina, en donde, si la concentración de tripsina está por encima del límite superior de la normalidad, el animal se trata durante un periodo de tiempo adecuado administrando al animal una cantidad terapéuticamente eficaz de una composición farmacéutica que comprende un portador farmacéuticamente aceptable y el compuesto N-α-(2,4,6- triisopropilfenilsulfonil)-3-hidroxiamidino-fenilalanina-4-etoxicarbonilpiperazida, los estereoisómeros, mezclas racémicas, metabolito, sal farmacéuticamente aceptable, cristal, o cualquier combinación de estos. En una modalidad, la afección no cancerosa es una enfermedad inflamatoria digestiva seleccionada del grupo que consiste en pancreatitis, gastritis, síndrome de intestino irritable y enfermedad inflamatoria intestinal. En una modalidad, la composición farmacéutica está en una forma administrable por vía oral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535376P | 2017-07-21 | 2017-07-21 | |
| US201762574449P | 2017-10-19 | 2017-10-19 | |
| US201762589734P | 2017-11-22 | 2017-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000096A1 true CL2020000096A1 (es) | 2020-08-28 |
Family
ID=65014605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000096A CL2020000096A1 (es) | 2017-07-21 | 2020-01-13 | Uso de wx-uk1 y su profármaco, wx-671, para el tratamiento de enfermedades no cancerosas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190022088A1 (es) |
| EP (1) | EP3654979A4 (es) |
| JP (1) | JP2020527582A (es) |
| KR (1) | KR20200031567A (es) |
| CN (1) | CN110785172A (es) |
| AU (1) | AU2018303799A1 (es) |
| CA (1) | CA3070037A1 (es) |
| CL (1) | CL2020000096A1 (es) |
| IL (1) | IL271878A (es) |
| PH (1) | PH12019502817A1 (es) |
| RU (1) | RU2020107706A (es) |
| SG (1) | SG11201912043QA (es) |
| WO (1) | WO2019016595A1 (es) |
| ZA (1) | ZA201908545B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494602B (zh) * | 2020-04-14 | 2023-06-02 | 广州领晟医疗科技有限公司 | 一种治疗急性胰腺炎的组合物及其用途 |
| CN111494392A (zh) * | 2020-04-14 | 2020-08-07 | 广州领晟医疗科技有限公司 | 一种用于治疗急性肺损伤的组合物及其应用 |
| CN113559100B (zh) * | 2021-08-30 | 2023-01-17 | 广州领晟医疗科技有限公司 | 一种治疗肺损伤的组合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534498A (en) * | 1992-01-30 | 1996-07-09 | Corvas International, Inc. | Trypsin inhibitors |
| US7342018B2 (en) * | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| AU2003206945A1 (en) * | 2002-02-22 | 2003-09-09 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of proteinase inhibitors in the treatment of autoimmune diseases |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| ES2509616T3 (es) * | 2009-06-25 | 2014-10-17 | Nestec S.A. | Procedimientos de diagnóstico del síndrome del intestino irritable |
-
2018
- 2018-07-13 JP JP2020502586A patent/JP2020527582A/ja active Pending
- 2018-07-13 WO PCT/IB2018/000881 patent/WO2019016595A1/en unknown
- 2018-07-13 SG SG11201912043QA patent/SG11201912043QA/en unknown
- 2018-07-13 KR KR1020197037453A patent/KR20200031567A/ko not_active Application Discontinuation
- 2018-07-13 US US16/034,815 patent/US20190022088A1/en not_active Abandoned
- 2018-07-13 AU AU2018303799A patent/AU2018303799A1/en not_active Abandoned
- 2018-07-13 CN CN201880042082.2A patent/CN110785172A/zh active Pending
- 2018-07-13 RU RU2020107706A patent/RU2020107706A/ru not_active Application Discontinuation
- 2018-07-13 CA CA3070037A patent/CA3070037A1/en not_active Abandoned
- 2018-07-13 EP EP18835233.0A patent/EP3654979A4/en not_active Withdrawn
-
2019
- 2019-12-13 PH PH12019502817A patent/PH12019502817A1/en unknown
- 2019-12-20 ZA ZA2019/08545A patent/ZA201908545B/en unknown
-
2020
- 2020-01-07 IL IL271878A patent/IL271878A/en unknown
- 2020-01-13 CL CL2020000096A patent/CL2020000096A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020107706A3 (es) | 2021-10-15 |
| US20190022088A1 (en) | 2019-01-24 |
| CA3070037A1 (en) | 2019-01-24 |
| RU2020107706A (ru) | 2021-08-23 |
| IL271878A (en) | 2020-02-27 |
| ZA201908545B (en) | 2021-02-24 |
| PH12019502817A1 (en) | 2020-09-14 |
| EP3654979A1 (en) | 2020-05-27 |
| CN110785172A (zh) | 2020-02-11 |
| EP3654979A4 (en) | 2021-04-14 |
| SG11201912043QA (en) | 2020-02-27 |
| WO2019016595A1 (en) | 2019-01-24 |
| JP2020527582A (ja) | 2020-09-10 |
| AU2018303799A1 (en) | 2019-12-19 |
| KR20200031567A (ko) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000096A1 (es) | Uso de wx-uk1 y su profármaco, wx-671, para el tratamiento de enfermedades no cancerosas. | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| CO2017011172A2 (es) | Compuestos de 1-ciano-pirrolidina como inhibidores de usp30 | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR087309A1 (es) | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| EA201200002A1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
| AR060516A1 (es) | Dihidrotienopirimidinas utilizables en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de pde4 y composiciones farmaceuticas que las contienen. | |
| DOP2007000079A (es) | Compuestos fenil amido heterocíclicos condensados | |
| EA201100391A1 (ru) | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы | |
| PE20212331A1 (es) | Derivados de pirrolotriazina para tratar enfermedades mediadas por kit y pdgfra | |
| AR057162A1 (es) | Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac) | |
| EA201200472A1 (ru) | Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
| BR112017017275A2 (pt) | composto, composição farmacêutica, método para o tratamento e uso do composto | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
| TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| CL2011000520A1 (es) | Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos. | |
| EA202190103A1 (ru) | Трициклические соединения |